Compare JDZG & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JDZG | PDSB |
|---|---|---|
| Founded | 2020 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.5M | 49.5M |
| IPO Year | 2024 | N/A |
| Metric | JDZG | PDSB |
|---|---|---|
| Price | $1.71 | $0.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 413.3K | ★ 762.5K |
| Earning Date | 12-17-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,680,742.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.19 | N/A |
| 52 Week Low | $0.73 | $0.70 |
| 52 Week High | $7.92 | $2.20 |
| Indicator | JDZG | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 64.22 | 48.50 |
| Support Level | $1.10 | $0.92 |
| Resistance Level | $1.85 | $1.01 |
| Average True Range (ATR) | 0.24 | 0.08 |
| MACD | 0.11 | -0.00 |
| Stochastic Oscillator | 79.45 | 24.99 |
Jiade Ltd specializes in providing one-stop comprehensive education supporting services to adult education institutions, through a wide range of software platform and auxiliary solutions. Auxiliary solutions encompass exam administration services and teaching support services throughout the entire teaching cycle. Specifically, the company offers pre-enrollment guidance on school/major selection and application strategy development, training for entrance exams, and assistance in the application process. The company also provides offline tutoring, exam administration services, guidance on graduation thesis, and social practice assistance included in the one-stop comprehensive education supporting services in the People's Republic of China.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.